Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/120730
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Moreno, PM | |
dc.creator | Pêgo, AP | |
dc.date.accessioned | 2019-06-25T12:08:37Z | - |
dc.date.available | 2019-06-25T12:08:37Z | - |
dc.date.issued | 2014 | |
dc.identifier.issn | 2296-2646 | |
dc.identifier.uri | https://hdl.handle.net/10216/120730 | - |
dc.description.abstract | Under clinical development since the early 90's and with two successfully approved drugs (Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a clinical drug to the market in the cancer field. Whilst many pre-clinical data has been generated, a lack of understanding still exists on how to efficiently tackle all the different challenges presented for cancer targeting in a clinical setting. Namely, effective drug vectorization, careful choice of target gene or synergistic multi-gene targeting are surely decisive, while caution must be exerted to avoid potential toxic, often misleading off-target-effects. Here a brief overview will be given on the nucleic acid chemistry advances that established oligonucleotide technologies as a promising therapeutic alternative and ongoing cancer related clinical trials. Special attention will be given toward a perspective on the hurdles encountered specifically in the cancer field by this class of therapeutic oligonucleotides and a view on possible avenues for success is presented, with particular focus on the contribution from nanotechnology to the field. | |
dc.description.sponsorship | The authors would like to acknowledge the FEDER funds through the Programa Operacional Factores de Competitividade - COMPETE and the Portuguese funds through FCT – Fundação para a Ciência e a Tecnologia (PTDC/CTM-NAN/115124/2009, HMSP-ICT/0020/2010 and PEst-C/SAU/LA0002/2013) that supported this work. Pedro M. D. Moreno is supported by a Marie Curie Action of the European Community’s Seventh Framework Program (PIEF-GA2 011300485). | |
dc.language.iso | eng | |
dc.publisher | Frontiers Media | |
dc.relation | info:eu-repo/grantAgreement/FCT/5876-PPCDTI/115124/PT | |
dc.relation | info:eu-repo/grantAgreement/FCT/5876-PPCDTI/116372/PT | |
dc.relation | info:eu-repo/grantAgreement/FCT/COMPETE/132934/PT | |
dc.relation.ispartof | Frontiers in Chemistry, vol. 2:87 | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Antisense | |
dc.subject | Cancer | |
dc.subject | Nanomedicine | |
dc.subject | Oligonucleotides | |
dc.subject | Therapeutics | |
dc.title | Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic | |
dc.type | Artigo em Revista Científica Internacional | |
dc.contributor.uporto | Instituto de Investigação e Inovação em Saúde | |
dc.identifier.doi | 10.3389/fchem.2014.00087 | |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fchem.2014.00087/full | |
Appears in Collections: | I3S - Artigo em Revista Científica Internacional |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fchem201400087.pdf | 844.18 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License